Airdrie, Scotland — Susan McGowan, a 58-year-old nurse who had served at University Hospital Monklands for over three decades, recently passed away due to complications associated with a new weight-loss medication, tirzepatide, marketed as Mounjaro. Her death, recorded as the result of multiple organ failure, septic shock, and pancreatitis, also lists the use of tirzepatide as a contributing factor.
McGowan had reportedly taken two injections of the prescribed weight-loss drug over approximately two weeks before her symptoms escalated, leading to her subsequent death on September 4. Her niece, Jade Campbell, described the rapid progression of McGowan’s illness, which led from initial stomach pains to a dire medical emergency, culminating in organ failure.
Mounjaro, approved this year for use as a weight-loss aid in the UK, functions as a GLP-1 receptor agonist. These drugs help patients feel fuller longer, potentially aiding significant weight loss. The approvals, albeit recent, come with restrictions, with prescriptions primarily provided to a limited number of patients by the National Health Service (NHS), due to factors including cost and availability.
The Medicines and Healthcare products Regulatory Agency (MHRA), which approved tirzepatide, reassures the public of the stringent monitoring protocols in place for new medications. MHRA’s Chief Safety Officer, Dr. Alison Cave, emphasized that the benefits of medications like tirzepatide often outweigh possible risks for most patients.
Despite rigorous safety and efficacy trials, adverse effects leading to severe outcomes, including death, have raised concerns. Public data disclosed by MHRA shows multiple reports of serious reactions linked to the drug. Between January and May of the following year, tirzepatide had 208 recorded incidents on the MHRA’s yellow card scheme, which tracks suspected adverse drug reactions, including 31 severe cases and one other suspected death.
The pharmaceutical manufacturer, Lilly, stands by its product, maintaining that patient safety remains their paramount concern. A company spokesperson asserted their commitment to the rigorous assessment of their medications and ongoing monitoring of their safety profile.
Adding to the broader discussions around weight-loss drugs, other similar treatments like Semaglutide, branded as Wegovy and Ozempic, have also been linked with suspected fatalities in the UK. Since their approval, these drugs have been cautiously welcomed by healthcare professionals aiming to address obesity, which remains a substantial health challenge across the nation.
Prof. Naveed Sattar, a metabolic medicine specialist at the University of Glasgow, pointed out that while individual adverse reactions could occur, the collective clinical trial data significantly supports the safety and benefit of these drugs for many individuals facing severe obesity.
In light of these discussions, some in the medical community and the public continue to scrutinize the rollouts of such weight-loss treatments, particularly when endorsed by governmental initiatives. A recent proposal by the UK government to distribute Mounjaro to assist unemployed individuals in returning to work has sparked debates concerning the timing and appropriateness of such measures.
As the debate continues, family members like Campbell urge those considering weight-loss injections to consult with healthcare providers to fully understand all possible options and the associated risks. The tragedy of McGowan’s death serves as a poignant reminder of the critical need for individual assessments in medical treatments, ensuring that the benefits truly outweigh the risks for each patient.